Welcome to our dedicated page for Acurx Pharmaceuticals news (Ticker: ACXP), a resource for investors and traders seeking the latest updates and insights on Acurx Pharmaceuticals stock.
Acurx Pharmaceuticals, Inc. develops small-molecule antibiotics for difficult-to-treat bacterial infections through a Gram-positive selective spectrum approach targeting DNA polymerase IIIC. Its pipeline includes ibezapolstat for Clostridioides difficile infection and additional DNA pol IIIC inhibitor candidates directed at Gram-positive pathogens such as MRSA, VRE, drug-resistant Streptococcus pneumoniae and B. anthracis.
Recurring ACXP news covers antibiotic development updates, microbiome data, scientific conference presentations, intellectual property for DNA pol IIIC inhibitors, financial results, registered offerings, warrant activity and investor-presentation announcements.
Acurx Pharmaceuticals (NASDAQ: ACXP) announced a registered direct offering of 1,289,980 shares at $3.25 per share, aggregating gross proceeds of approximately $4.225 million. The offering includes 130,769 pre-funded warrants sold to a U.S. institutional investor, with executives purchasing shares at $3.80. Series A and B unregistered warrants will also be issued to investors. Closing is anticipated around July 27, 2022, subject to customary conditions. The company intends to use net proceeds for general corporate purposes.
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) reported its financial results for Q1 2022, revealing a net loss of $2.7 million or $0.26 per share, up from a loss of $1.5 million or $0.21 per share in Q1 2021. R&D expenses rose to $0.8 million, compared to $0.1 million in the prior year, mainly due to Phase 2b trial costs. The company is advancing its Phase 2b trial for ibezapolstat targeting C. difficile, with enrollment expected to finish in late 2022. In addition, partnerships continue with Leiden University for further R&D.
Acurx Pharmaceuticals (NASDAQ: ACXP) will release its 2022 Q1 financial results on May 11, 2022, at 8:30 am ET. Following the results, a conference call will be held where CEO David P. Luci and CFO Robert G. Shawah will provide updates. The company is advancing its antibiotic ibezapolstat for treating C. difficile infections, with successful Phase 1 and 2a trials showing 100% clinical cure rates. Ibezapolstat has received FDA designations for streamlined development due to the urgent need for new treatments.
Acurx Pharmaceuticals (NASDAQ: ACXP) reported its financial and operational results for Q4 and full year 2021. The company is enrolling in a Phase 2b trial for its lead antibiotic, ibezapolstat, aimed at treating C. difficile infections. The trial compares ibezapolstat's efficacy against vancomycin. R&D expenses for the year decreased to $2.0 million, while general and administrative expenses rose significantly to $10.8 million, primarily due to stock-based compensation and increased professional fees. The net loss for 2021 was $12.7 million, with a loss per share of $(1.49).
Acurx Pharmaceuticals (NASDAQ: ACXP) announced that President & CEO David P. Luci will present at the 2022 Virtual Growth Conference hosted by Maxim Group LLC from March 28-30, 2022. Luci's fireside chat is scheduled for March 28 at 9:30 am ET. This event will feature various sectors, including Biotech and Healthcare. Acurx's lead antibiotic candidate, ibezapolstat, has shown promising results in its Phase 2a trial for C. difficile Infection, with a 100% efficacy in the primary and secondary endpoints. Acurx is currently enrolling for a Phase 2b trial comparing ibezapolstat to vancomycin.
Acurx Pharmaceuticals (NASDAQ: ACXP) will release its financial results for Q4 2021 and fiscal year 2021 on March 17, 2022, at 8:30 AM ET. The company will hold a conference call to discuss the results. Acurx is advancing its Phase 2 clinical trial of ibezapolstat, targeting C. difficile infections. The completed Phase 2a segment showed complete eradication of C. difficile by day three of treatment, with promising data on microbiome health. The ongoing Phase 2b trial will enroll 64 patients, comparing ibezapolstat to vancomycin.
Acurx Pharmaceuticals (NASDAQ: ACXP) announced positive results from its Phase 2a clinical trial of ibezapolstat for treating Clostridioides difficile Infection (CDI), published in Clinical Infectious Diseases. All 10 patients in the trial achieved both primary and secondary efficacy endpoints, demonstrating a 100% Clinical Cure rate at the end of treatment. The trial reports favorable microbiome changes, including beneficial increases in Actinobacteria and Firmicutes. Acurx is now enrolling for a Phase 2b trial comparing ibezapolstat to vancomycin, with the goal of confirming non-inferiority.
Acurx Pharmaceuticals (NASDAQ: ACXP) has enrolled the first patient in its Phase 2b clinical trial of ibezapolstat, targeting Clostridioides difficile infection (CDI). This trial, consisting of 64 patients, aims to demonstrate non-inferiority compared to vancomycin, the current standard treatment. Previous Phase 2a results showed 100% eradication of CDI without recurrence, and favorable effects on the gut microbiome. Ibezapolstat has received FDA's QIDP and Fast Track designations, indicating a potential breakthrough in addressing CDI, which poses significant health risks.
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) reported its financial and operational results for Q3 2021, highlighting 12 clinical trial sites activated for a Phase 2b trial of ibezapolstat targeting C. difficile infection (CDI). The Phase 2a trial indicated a 100% clinical cure rate. Financially, R&D expenses rose to $1.1 million, while SG&A expenses surged to $3.5 million, resulting in a net loss of $4.6 million. As of September 30, 2021, the company has $14.5 million in cash.
Acurx Pharmaceuticals (NASDAQ: ACXP) announced new findings from its Phase 2a trial of ibezapolstat for treating C. difficile infections (CDI), presented at the 9th International C. diff Conference on November 5, 2021. The trial highlighted complete eradication of C. difficile by day three and growth of healthy microbiota. Notably, ibezapolstat therapy increased secondary bile acids, suggesting reduced CDI recurrence risk compared to vancomycin. The upcoming Phase 2b trial will further evaluate pharmacokinetics and microbiome changes as Acurx looks to continue its positive trajectory in CDI treatment.